Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the efficacy, safety and tolerability of HTS-519 Inserts in the treatment of mild to moderate toenail fungus disease of the big toenail.
Open label, single-site
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HTS-519 Insert | Experimental | Active treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HTS-519 Insert | Drug | Maximum feasible dose of HTS-519 Insert per diseased nail |
|
| Measure | Description | Time Frame |
|---|---|---|
| Treatment Related Adverse Events | Frequency and severity of Treatment Related Adverse Events | Up to 48 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Thomas Tremblay, RN, BSN | Hallux, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| OrthoArizona - East Valley Foot & Ankle Specialists | Mesa | Arizona | 85206 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | HTS-519 Insert | Active treatment HTS-519 Insert: Maximum feasible dose of HTS-519 Insert per diseased nail |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | HTS-519 Insert | Active treatment HTS-519 Insert: Maximum feasible dose of HTS-519 Insert per diseased nail |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Treatment Related Adverse Events | Frequency and severity of Treatment Related Adverse Events | Safety Population: All Enrolled | Posted | Count of Participants | Participants | Up to 48 weeks |
|
|
48 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | HTS-519 Insert | Active treatment HTS-519 Insert: Maximum feasible dose of HTS-519 Insert per diseased nail |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Leg edema | Investigations | MedDRA (Unspecified) | Systematic Assessment | Severe Right Leg Edema/ Not related |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Mild Punctate Bleeding | General disorders | MedDRA (Unspecified) | Systematic Assessment | Preferred Term = Implant site haematoma |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Thomas M Tremblay, RN BSN, Vice President of Clinical Affairs | Hallux, Inc. | (415) 305-3491 | ttremblay@halluxinc.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Sep 12, 2017 | Sep 5, 2019 | Prot_SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D014009 | Onychomycosis |
| ID | Term |
|---|---|
| D014005 | Tinea |
| D003881 | Dermatomycoses |
| D009181 | Mycoses |
| D001423 | Bacterial Infections and Mycoses |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Participants |
|
| Age, Continuous | Mean | Full Range | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
|
| 0 |
| 30 |
| 2 |
| 30 |
| 28 |
| 30 |
|
| Spinal Fusion Surgery | Surgical and medical procedures | MedDRA (Unspecified) | Systematic Assessment | L4-S1 Spinal Fusion/ Not related |
|
|
| Mild Subungual Hematoma | General disorders | MedDRA (Unspecified) | Systematic Assessment | Preferred Term = Implant site haemorrhage |
|
| Mild Pain in Toe | Investigations | MedDRA (Unspecified) | Systematic Assessment | Preferred Term = Pain in Toe |
|
| Mild Onycholysis | Skin and subcutaneous tissue disorders | MedDRA (Unspecified) | Systematic Assessment | Preferred Term = Onycholysis |
|
Not provided
Not provided
| D007239 |
| Infections |
| D012874 | Skin Diseases, Infectious |
| D009260 | Nail Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |